Apnimed, a biotech company backed by Shionogi, Raises $192 Million in U.S. IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in its initial public offering (IPO) in the United States. The IPO was expanded and priced at the top of the offering range.
Source:彭博市场 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Liquidity Crunch in Cryptocurrency Mining: Causes and Analysis of the Current Situation in 2026
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
Microsoft It is up 3.02% today and is currently trading at $464.720
-
5
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
6
Federal Appeals Court Rejects Bid to Block Trump’s Mail Voting Restrictions
-
7
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
8
India’s Kerala Struggles to Care for Aging Population with Low Fertility Rate
-
9
Donald Trump TRUMP (TRUMP) 2026 Outlook: Analysis of Price Trends and Key Influencing Factors
-
10
Israeli West Bank Settler Tells BBC Attacks on Palestinians Are Justified as Revenge, Equating One Jewish Life to "10 Million" Palestinians
Markets Today
Recommended Reading






